PMID- 36860259
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230303
IS  - 2304-3881 (Print)
IS  - 2304-389X (Electronic)
IS  - 2304-3881 (Linking)
VI  - 12
IP  - 1
DP  - 2023 Feb 28
TI  - Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as 
      first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 
      clinical trial.
PG  - 37-44
LID - 10.21037/hbsn-21-172 [doi]
AB  - BACKGROUND: This study aimed to evaluate the efficacy and safety of a new 
      combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule 
      (S-1) for patients with advanced biliary tract carcinoma (BTC). METHODS: Patients 
      were treated with nab-paclitaxel at a dose of 125 mg/m(2) on day 1 and 8, and 
      S-1, 80 to 120 mg/day on days 1-14 of a 21-day cycle. Treatments were repeated 
      until disease progression or unacceptable toxicity occurred. The primary endpoint 
      was objective response rate (ORR). The secondary endpoints were median 
      progression-free survival (PFS), overall survival (OS), and adverse events (AEs). 
      RESULTS: The number of patients enrolled were 54, and 51 patients were evaluated 
      for efficacy. A total of 14 patients achieved partial response (PR) with an ORR 
      of 27.5%. The ORR varied by sites, with 53.8% (7/13) for gallbladder carcinoma, 
      18.4% (7/38) for cholangiocarcinoma. The most common grade 3 or 4 toxicities were 
      neutropenia and stomatitis. The median PFS and OS were 6.0 and 13.2 months, 
      respectively. CONCLUSIONS: The combination of nab-paclitaxel with S-1 showed 
      explicit antitumor activities and favorable safety profile in advanced BTC and 
      could serve as a potential non-platinum and -gemcitabine-based regimen.
CI  - 2023 Hepatobiliary Surgery and Nutrition. All rights reserved.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Sun, Yongkun
AU  - Sun Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Jiang, Zhichao
AU  - Jiang Z
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Qu, Wang
AU  - Qu W
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Gong, Caifeng
AU  - Gong C
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Zhou, Aiping
AU  - Zhou A
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20211018
PL  - China (Republic : 1949- )
TA  - Hepatobiliary Surg Nutr
JT  - Hepatobiliary surgery and nutrition
JID - 101600750
PMC - PMC9944545
OTO - NOTNLM
OT  - Biliary tract adenocarcinoma
OT  - chemotherapy
OT  - nab-paclitaxel
OT  - tegafur gimeracil oteracil potassium capsule (S-1)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-172/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/03/03 06:00
MHDA- 2023/03/03 06:01
PMCR- 2023/02/28
CRDT- 2023/03/02 02:04
PHST- 2021/04/30 00:00 [received]
PHST- 2021/09/10 00:00 [accepted]
PHST- 2023/03/02 02:04 [entrez]
PHST- 2023/03/03 06:00 [pubmed]
PHST- 2023/03/03 06:01 [medline]
PHST- 2023/02/28 00:00 [pmc-release]
AID - hbsn-12-01-37 [pii]
AID - 10.21037/hbsn-21-172 [doi]
PST - ppublish
SO  - Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):37-44. doi: 10.21037/hbsn-21-172. Epub 
      2021 Oct 18.